CEMP Cempra, Inc.

4.20
+0  (9%)
Previous Close 3.85
Open 3.90
Price To book 1.10
Market Cap 220.05M
Shares 52,392,000
Volume 1,974,747
Short Ratio 2.24
Av. Daily Volume 2,764,770

SEC filingsSee all SEC filings

  1. 8-K - Current report 17683979
  2. 8-K - Current report 17666504
  3. POS AM - Post-Effective amendments for registration statement 17660155
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17644787
  5. 8-K - Current report 17644689

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due by the end of 2017.
Taksta - Fusidic acid
Refractory infections in bones and joints
CRL announced December 29, 2016. Further trials required.
Solithera - intravenous
Community-acquired bacterial pneumonia (CABP)
CRL announced December 29, 2016. Further trials required.
Solithera - oral
Community-acquired bacterial pneumonia (CABP)
Phase 2 interim data released September 30, 2016. Noted February 28, 2017 that development has been suspended due to lack of efficacy.
Solithromycin
NASH
Phase 3 initiated August 2014. Enrollment completed December 2015 but decided to increase enrollment. Noted January 9, 2017 that extension enrollment has been slower than envisaged. Finally noted February 28, 2017 that data did not demonstrate non-inferiority (NI) to standard of care.
Solithromycin
Uncomplicated urogenital gonococcal infections
Phase 3 data released February 24, 2017 - endpoints met.
Taksta - Fusidic acid
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 2 trial discontinued - noted January 9, 2017.
Solithromycin
COPD

Latest News

  1. Cempra, Inc. :CEMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. Cempra, Inc. :CEMP-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  3. With $230M in cash, Cempra’s “strategic business options” wide-ranging
  4. CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
  6. Pharmaceutical, marketing firms to lay off 136 workers statewide
  7. CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. CEMPRA, INC. Financials
  9. Cempra to Present at 29th Annual ROTH Conference
  10. From Cempra to Lowe's: North Carolina's 2017 layoffs by the numbers
  11. Cempra cuts workforce by 67 percent
  12. Edited Transcript of CEMP earnings conference call or presentation 28-Feb-17 1:45pm GMT
  13. CEMPRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  14. Cempra reports 4Q loss
  15. Cempra reports 4Q loss
  16. Q4 2016 Cempra Inc Earnings Release - Before Market Open
  17. 6:48 am Cempra misses by $0.04, beats on revs; provides corporate update
  18. Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  19. Cempra Skin Infection Drug Succeeds in Trial
  20. Monday Movers In Biotech: Cempra Inc (CEMP) And IntelliPharmaCeutics Intl Inc (USA) (IPCI)